Inozyme brings $67M to the bank to build up its calcification-focused rare disease pipeline
Inozyme founder Axel Bolte is intensifying his faith in his rare-disease upstart’s lead experimental drug by testing it for a second indication focused on disorders characterized by abnormal calcification. An expanded clinical program for the drug — which is being readied for human testing — needs more capital, and the biotech has raised some in a fresh $67 million round, led by Pivotal bioVenture Partners and Sofinnova Investments.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.